TRUDI: TDXD+Durva in HER2+/Low IBC
TRUDI: TDXD+Durva in HER2+/Low IBC
Recruiting · NCT05795101 · Registry updated 2026-10-09Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| TRUDI: TDXD+Durva in HER2+/Low IBC | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, inflammatory breast carcinoma, invasive breast carcinoma, neoplasm, skin disorder | Recruiting | Phase 2 | 2026-10-09 | NCT05795101 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| AstraZeneca | 806 |
| Daiichi Sankyo | 144 |
| Filipa Lynce, MD | 1 |
3 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Brigham and Women's Hospital | Boston | United States | 60 |
| Dana Farber Cancer Institute | Boston | United States | 300 |
| University of Texas MD Anderson Cancer Center | Houston | United States | 192 |